| Catalog # | H1910-40J |
| Principle of the Assay | The purified Anti-HBe is coated on the solid phase of multi-wells. Serum sample, recombinant HBeAg and horseradish peroxidase labeled with Anti-HBe (conjugated) are added to coated wells, and form a competitive combination. After incubation, if Anti-HBe content is high in the sample, a complex of HBeAg-Anti-HBe-Anti-HBe labeled with HRP will form. The wells are washed to remove the complex, and incubated with substrate (TMB), subsequently producing no color change or little color change. If Anti-HBe is not present in the sample, there will be significant color change. The test is sensitive, reproducible and easy to operate. |
| The Anti-Hepatitis B Virus E Antigen (HBeAg) ELISA Kit is a qualitative in vitro enzyme immunoassay for the detection of anti-HBe in human serum or plasma. |
| Kit Components | H1910-40J1: Microtiter Plate, 1x96wells |
| H1910-40J2: Enzyme Conjugate, 1x6ml |
| H1910-40J3: Positive Control Serum, 1x500ul |
| H1910-40J4: Negative Control Serum, 1x500ul |
| H1910-40J5: Wash Buffer (20X), 1x30ml |
| H1910-40J6: Substrate A, 1x6ml |
| H1910-40J7: Substrate B, 1x6ml |
| H1910-40J8: Stop Solution, 1x6ml |
| H1910-40J9: Neutralization Reagent, 1x6ml |
| Interpretation of Results | Cut-off Value (COV) Calculation: |
| COV = average OD450 of negative controls X 0.5 |
| Positive | OD450 of sample < COV |
| Negative: OD450 of sample COV |
| Invalid: If the OD of negative control is below or equal to 1.000, the result is invalid. In any event, repeat the test. If the problem persists, contact technical support. |
| Performance Characteristics | Sensitivity: 4NCU/ml (per Biological Reference Reagents of Chinese Clinical Test Center), OD 0.600 |
| Specificity: The average OD of 20 normal negative smples is 2.00 |
| Precision: %CV 20% (n= 10) |
| Storage and Stability | Store all kit components at 4C. Kit is stable for 6 months. |
| Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
